MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...
Copyright © 2024omega1medianewsglobalnetwork. All Rights Reserved http://www.endless5dollarpayments.com